Q15907
PR
Gene name |
RAB11B (YPT3) |
Protein name |
Ras-related protein Rab-11B |
Names |
GTP-binding protein YPT3 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:9230 |
EC number |
3.6.5.2: Acting on GTP; involved in cellular and subcellular movement |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
4 structures for Q15907
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2F9L | X-ray | 155 A | A | 8-205 | PDB |
| 2F9M | X-ray | 195 A | A | 8-205 | PDB |
| 4OJK | X-ray | 266 A | A/B | 8-205 | PDB |
| AF-Q15907-F1 | Predicted | AlphaFoldDB |
140 variants for Q15907
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
|
RCV000523787 VAR_080598 CA403709616 rs1555690779 |
22 | V>M | Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter NDAGSCW [ClinVar, UniProt] | Yes |
ClinGen ClinVar UniProt Ensembl dbSNP |
|
CA403711179 RCV001052890 rs1555690804 VAR_080599 RCV000520305 |
68 | A>T | Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter NDAGSCW [ClinVar, UniProt] | Yes |
ClinGen ClinVar UniProt Ensembl dbSNP |
|
rs1971454639 RCV001329826 |
195 | V>M | Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter [ClinVar] | Yes |
ClinVar dbSNP |
|
rs1358098381 CA403706964 |
2 | G>R | No |
ClinGen gnomAD |
|
|
CA9156252 rs768804811 |
3 | T>A | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA304970140 rs1039303139 |
3 | T>N | No |
ClinGen Ensembl |
|
|
CA304970160 rs920560749 |
4 | R>Q | No |
ClinGen Ensembl |
|
|
rs763624059 CA9156257 |
5 | D>E | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA9156256 rs773651562 |
5 | D>N | No |
ClinGen ExAC gnomAD |
|
|
CA9156258 CA403707068 rs766981683 |
7 | E>D | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1047798308 CA304970180 |
7 | E>K | No |
ClinGen gnomAD |
|
|
CA403707078 rs1353087352 |
8 | Y>F | No |
ClinGen gnomAD |
|
|
CA403709477 rs1568228630 |
18 | G>R | No |
ClinGen Ensembl |
|
|
rs770191495 CA9156289 |
34 | N>S | No |
ClinGen ExAC gnomAD |
|
|
CA403710117 rs1258251137 |
36 | F>V | No |
ClinGen TOPMed |
|
|
rs778110677 CA9156290 |
37 | N>I | No |
ClinGen ExAC gnomAD |
|
|
CA403710383 rs1599687403 |
43 | T>P | No |
ClinGen Ensembl |
|
|
rs1216134182 CA403710417 |
44 | I>V | No |
ClinGen gnomAD |
|
|
rs1487229487 CA403710475 |
45 | G>S | No |
ClinGen gnomAD |
|
| TCGA novel | 48 | F>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA403710713 rs1300751200 |
51 | R>H | No |
ClinGen gnomAD |
|
|
rs951143696 CA304975074 |
52 | S>G | No |
ClinGen Ensembl |
|
|
CA403710859 rs760153019 |
54 | Q>H | No |
ClinGen ExAC gnomAD |
|
|
rs1347989637 CA403710883 |
55 | V>A | No |
ClinGen gnomAD |
|
|
rs754448304 CA304975084 |
55 | V>L | No |
ClinGen Ensembl |
|
|
CA304975087 rs866295821 |
57 | G>D | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen Ensembl NCI-TCGA |
|
CA9156299 rs753519320 |
57 | G>S | No |
ClinGen ExAC gnomAD |
|
|
rs1342650519 CA403710981 |
59 | T>N | No |
ClinGen gnomAD |
|
|
CA403710988 rs1374571760 |
60 | I>L | No |
ClinGen gnomAD |
|
|
rs761405279 CA9156300 |
62 | A>V | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
CA403711327 rs1288425927 |
74 | R>C | No |
ClinGen gnomAD |
|
|
CA9156303 rs541363844 |
74 | R>H | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
rs1260781681 CA403711371 |
76 | I>N | No |
ClinGen gnomAD |
|
|
rs992140697 CA304975119 |
79 | A>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen Ensembl NCI-TCGA |
|
CA403711785 rs1599688387 |
80 | Y>D | No |
ClinGen Ensembl |
|
|
CA403711813 rs1345334664 |
82 | R>S | No |
ClinGen gnomAD |
|
|
CA403711845 rs1276015885 |
84 | A>V | No |
ClinGen gnomAD |
|
|
rs1199026573 CA403711863 |
86 | G>D | No |
ClinGen gnomAD |
|
|
CA403711871 rs1456363974 |
87 | A>T | No |
ClinGen gnomAD |
|
|
rs1247388215 CA403711884 |
88 | L>M | No |
ClinGen gnomAD |
|
|
rs1171043031 CA403711932 |
92 | D>N | No |
ClinGen gnomAD |
|
|
rs1250398546 CA403711961 COSM1169356 |
94 | A>T | Variant assessed as Somatic; impact. haematopoietic_and_lymphoid_tissue [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated NCI-TCGA TOPMed |
|
CA403712002 rs1173266627 |
96 | H>Y | No |
ClinGen gnomAD |
|
| TCGA novel | 97 | L>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1599688430 CA403712031 |
97 | L>P | No |
ClinGen Ensembl |
|
|
CA884315612 rs1347024677 |
99 | Y>* | No |
ClinGen TOPMed |
|
|
rs780413163 CA9156332 |
99 | Y>C | No |
ClinGen ExAC gnomAD |
|
|
CA403712220 rs1437902263 |
102 | V>L | No |
ClinGen gnomAD |
|
|
rs1437902263 CA403712211 |
102 | V>M | No |
ClinGen gnomAD |
|
|
rs1404756675 CA403712262 |
103 | E>Q | No |
ClinGen TOPMed |
|
|
rs1272779232 CA403712327 |
104 | R>H | No |
ClinGen gnomAD |
|
| TCGA novel | 105 | W>* | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA403712534 rs1329829240 |
110 | R>Q | No |
ClinGen TOPMed |
|
|
CA9156335 rs776189936 |
110 | R>W | No |
ClinGen ExAC gnomAD |
|
|
CA304976878 rs886597469 |
111 | D>E | No |
ClinGen TOPMed gnomAD |
|
|
rs769527918 CA9156337 |
113 | A>T | No |
ClinGen ExAC gnomAD |
|
|
CA403712710 rs1290426255 |
114 | D>G | No |
ClinGen gnomAD |
|
|
rs375511185 CA9156338 |
115 | S>N | No |
ClinGen ExAC gnomAD |
|
|
rs375511185 CA304976902 |
115 | S>T | No |
ClinGen ExAC gnomAD |
|
|
CA9156339 rs762618124 |
117 | I>V | No |
ClinGen ExAC gnomAD |
|
|
rs868743721 CA304976907 |
118 | V>I | No |
ClinGen TOPMed gnomAD |
|
|
CA9156342 rs759616082 |
119 | I>V | No |
ClinGen ExAC gnomAD |
|
|
CA304976939 rs1022889829 |
120 | M>L | No |
ClinGen TOPMed |
|
| TCGA novel | 120 | M>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1393502140 CA403713015 |
121 | L>P | No |
ClinGen gnomAD |
|
|
CA304976942 rs11556319 |
122 | V>L | No |
ClinGen Ensembl |
|
| TCGA novel | 123 | G>D | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA403714516 rs1599688528 |
127 | D>A | No |
ClinGen Ensembl |
|
|
rs1599688536 CA403714553 |
129 | R>S | No |
ClinGen Ensembl |
|
|
CA9156345 rs757250564 |
130 | H>Q | No |
ClinGen ExAC gnomAD |
|
|
rs765316562 CA9156346 |
132 | R>W | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA gnomAD |
|
rs1279655419 CA403714646 |
133 | A>S | No |
ClinGen gnomAD |
|
|
CA9156347 rs750629022 |
134 | V>L | No |
ClinGen ExAC gnomAD |
|
|
rs1599688560 CA403714689 |
135 | P>L | No |
ClinGen Ensembl |
|
|
rs758588165 CA9156348 |
136 | T>I | No |
ClinGen ExAC gnomAD |
|
|
CA403714761 rs1208175024 |
138 | E>* | No |
ClinGen gnomAD |
|
|
rs1208175024 CA403714758 |
138 | E>K | No |
ClinGen gnomAD |
|
|
rs747366868 CA9156350 |
140 | R>C | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
rs374943563 CA9156351 |
140 | R>H | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs374943563 CA403714838 |
140 | R>P | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
CA9156353 rs373086696 |
141 | A>T | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD |
| TCGA novel | 141 | A>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA403714920 rs1263418323 |
142 | F>Y | No |
ClinGen TOPMed |
|
|
CA403714965 rs772721088 |
143 | A>S | No |
ClinGen ExAC gnomAD |
|
|
CA9156355 rs772721088 |
143 | A>T | No |
ClinGen ExAC gnomAD |
|
|
rs1054368041 CA304976991 |
143 | A>V | No |
ClinGen gnomAD |
|
| TCGA novel | 144 | E>* | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA403714981 rs1163141402 |
144 | E>K | No |
ClinGen gnomAD |
|
| TCGA novel | 145 | K>N | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1171216764 CA403715233 |
146 | N>K | No |
ClinGen gnomAD |
|
|
rs1402360969 CA403715258 |
147 | N>S | No |
ClinGen gnomAD |
|
|
rs756581801 CA9156372 |
149 | S>F | No |
ClinGen ExAC gnomAD |
|
|
CA403715288 rs1434285419 |
149 | S>P | No |
ClinGen gnomAD |
|
|
rs937126014 CA403715419 |
151 | I>M | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
|
rs1393998917 CA403715424 |
152 | E>K | No |
ClinGen TOPMed gnomAD |
|
|
rs1393998917 CA403715426 |
152 | E>Q | No |
ClinGen TOPMed gnomAD |
|
|
rs748820048 CA9156374 |
157 | D>E | No |
ClinGen ExAC gnomAD |
|
|
rs893032942 CA304977190 |
157 | D>N | No |
ClinGen Ensembl |
|
|
rs770759610 CA403715693 COSM715632 |
160 | N>K | lung Variant assessed as Somatic; 0.0 impact. [Cosmic, NCI-TCGA] | No |
ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
|
CA9156376 rs778674562 |
161 | V>I | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs372364290 CA304977217 |
163 | E>G | No |
ClinGen ESP TOPMed gnomAD |
|
|
rs11556321 CA304977224 |
167 | N>D | No |
ClinGen Ensembl |
|
|
CA304977228 rs1022148424 |
167 | N>S | No |
ClinGen TOPMed |
|
|
CA304977231 rs1041662391 |
169 | L>P | No |
ClinGen TOPMed |
|
|
rs553410398 CA9156378 |
170 | T>I | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA403716333 rs754387016 |
173 | Y>C | No |
ClinGen ExAC gnomAD |
|
|
CA9156413 rs754387016 |
173 | Y>F | No |
ClinGen ExAC gnomAD |
|
|
CA9156415 rs764840955 |
174 | R>C | No |
ClinGen ExAC gnomAD |
|
|
rs749947672 CA9156416 |
174 | R>H | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs749947672 CA403716356 |
174 | R>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs921864727 CA304978319 |
176 | V>M | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 182 | A>G | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA9156420 rs150053146 |
182 | A>T | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ESP ExAC NCI-TCGA TOPMed gnomAD |
|
rs1166765790 CA403716491 |
182 | A>V | No |
ClinGen gnomAD |
|
|
CA403716495 rs1348235869 |
183 | D>H | No |
ClinGen gnomAD |
|
|
CA403716517 rs1299045693 |
184 | R>C | No |
ClinGen TOPMed gnomAD |
|
|
rs202233072 CA9156423 |
185 | A>T | No |
ClinGen 1000Genomes ExAC TOPMed gnomAD |
|
|
CA403716563 rs1471606469 |
186 | A>V | No |
ClinGen TOPMed |
|
|
rs371272699 CA403716592 |
187 | H>Q | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs1599689234 CA403716623 |
189 | E>K | No |
ClinGen Ensembl |
|
|
CA9156428 rs760756275 |
190 | S>C | No |
ClinGen ExAC gnomAD |
|
|
CA9156430 rs776791936 |
191 | P>L | No |
ClinGen ExAC gnomAD |
|
|
CA403716845 rs1483430107 |
197 | D>A | No |
ClinGen gnomAD |
|
|
rs1599689260 CA403716892 |
199 | S>T | No |
ClinGen Ensembl |
|
|
COSM3404810 CA9156437 rs754522300 |
200 | V>M | Variant assessed as Somatic; 0.0 impact. central_nervous_system [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
|
CA403716950 rs1226766733 |
201 | P>L | No |
ClinGen TOPMed |
|
|
CA403716969 rs1382440837 |
202 | P>L | No |
ClinGen gnomAD |
|
|
CA403716996 rs1418126002 |
203 | T>I | No |
ClinGen TOPMed gnomAD |
|
|
rs377033835 COSM3773236 CA9156439 |
204 | T>M | Variant assessed as Somatic; 0.0 impact. pancreas [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
|
rs142408908 CA9156442 |
206 | G>R | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs564037425 CA9156443 |
209 | P>S | No |
ClinGen 1000Genomes ExAC gnomAD |
|
| TCGA novel | 210 | N>I | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs775370486 CA9156444 |
210 | N>K | No |
ClinGen ExAC gnomAD |
|
|
rs1355161342 CA403717211 |
211 | K>R | No |
ClinGen gnomAD |
|
|
rs747256929 CA9156445 |
212 | L>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA403717236 rs1283032090 |
212 | L>P | No |
ClinGen gnomAD |
|
|
rs552481060 CA304978446 |
213 | Q>R | No |
ClinGen gnomAD |
|
|
CA9156446 rs768753557 |
217 | N>D | No |
ClinGen ExAC gnomAD |
|
|
CA403717385 rs1599689296 |
217 | N>T | No |
ClinGen Ensembl |
|
|
rs1599689299 CA403717419 |
219 | L>C | No |
ClinGen Ensembl |
1 associated diseases with Q15907
[MIM: 617807]: Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (NDAGSCW)
An autosomal dominant neurodevelopmental disorder apparent in infancy and characterized by severe intellectual disability with absent speech, epilepsy, and hypotonia. Additionally, visual problems, musculoskeletal abnormalities, and microcephaly can be present. Brain imaging shows decreased cortical white matter, often with decreased cerebellar white matter, thin corpus callosum, and thin brainstem. {ECO:0000269|PubMed:29106825}. Note=The disease is caused by variants affecting the gene represented in this entry.
Without disease ID
- An autosomal dominant neurodevelopmental disorder apparent in infancy and characterized by severe intellectual disability with absent speech, epilepsy, and hypotonia. Additionally, visual problems, musculoskeletal abnormalities, and microcephaly can be present. Brain imaging shows decreased cortical white matter, often with decreased cerebellar white matter, thin corpus callosum, and thin brainstem. {ECO:0000269|PubMed:29106825}. Note=The disease is caused by variants affecting the gene represented in this entry.
1 regional properties for Q15907
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Small GTP-binding protein domain | 10 - 168 | IPR005225 |
Functions
| Description | ||
|---|---|---|
| EC Number | 3.6.5.2 | Acting on GTP; involved in cellular and subcellular movement |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
11 GO annotations of cellular component
| Name | Definition |
|---|---|
| anchoring junction | A cell junction that mechanically attaches a cell (and its cytoskeleton) to neighboring cells or to the extracellular matrix. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| endosome | A vacuole to which materials ingested by endocytosis are delivered. |
| extracellular exosome | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| Golgi apparatus | A membrane-bound cytoplasmic organelle of the endomembrane system that further processes the core oligosaccharides (e.g. N-glycans) added to proteins in the endoplasmic reticulum and packages them into membrane-bound vesicles. The Golgi apparatus operates at the intersection of the secretory, lysosomal, and endocytic pathways. |
| phagocytic vesicle | A membrane-bounded intracellular vesicle that arises from the ingestion of particulate material by phagocytosis. |
| phagocytic vesicle membrane | The lipid bilayer surrounding a phagocytic vesicle. |
| recycling endosome | An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane. |
| recycling endosome membrane | The lipid bilayer surrounding a recycling endosome. |
| synaptic vesicle | A secretory organelle, typically 50 nm in diameter, of presynaptic nerve terminals; accumulates in high concentrations of neurotransmitters and secretes these into the synaptic cleft by fusion with the 'active zone' of the presynaptic plasma membrane. |
| synaptic vesicle membrane | The lipid bilayer surrounding a synaptic vesicle. |
6 GO annotations of molecular function
| Name | Definition |
|---|---|
| cadherin binding | Binding to cadherin, a type I membrane protein involved in cell adhesion. |
| G protein activity | A molecular function regulator that cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins to regulate cellular processes. Intrinsic GTPase activity returns the G protein to its GDP-bound state. The return to the GDP-bound state can be accelerated by the action of a GTPase-activating protein (GAP). |
| GDP binding | Binding to GDP, guanosine 5'-diphosphate. |
| GTP binding | Binding to GTP, guanosine triphosphate. |
| GTPase activity | Catalysis of the reaction: GTP + H2O = GDP + H+ + phosphate. |
| myosin V binding | Binding to a class V myosin; myosin V is a dimeric molecule involved in intracellular transport. |
15 GO annotations of biological process
| Name | Definition |
|---|---|
| amyloid-beta clearance by transcytosis | The process in which amyloid-beta is removed from extracellular brain regions by cell surface receptor-mediated endocytosis, followed by transcytosis across the blood-brain barrier. |
| cellular response to acidic pH | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a pH stimulus with pH < 7. pH is a measure of the acidity or basicity of an aqueous solution. |
| constitutive secretory pathway | A process of exocytosis found in all eukaryotic cells, in which transport vesicles destined for the plasma membrane leave the trans-Golgi network in a steady stream. Upon exocytosis, the membrane proteins and lipids in these vesicles provide new components for the plasma membrane, and the soluble proteins inside the vesicles are released into the extracellular space. |
| endocytic recycling | The directed movement of membrane-bounded vesicles from endosomes back to the plasma membrane, a trafficking pathway that promotes the recycling of internalized transmembrane proteins. |
| establishment of protein localization to membrane | The directed movement of a protein to a specific location in a membrane. |
| exocytosis | A process of secretion by a cell that results in the release of intracellular molecules (e.g. hormones, matrix proteins) contained within a membrane-bounded vesicle. Exocytosis can occur either by full fusion, when the vesicle collapses into the plasma membrane, or by a kiss-and-run mechanism that involves the formation of a transient contact, a pore, between a granule (for exemple of chromaffin cells) and the plasma membrane. The latter process most of the time leads to only partial secretion of the granule content. Exocytosis begins with steps that prepare vesicles for fusion with the membrane (tethering and docking) and ends when molecules are secreted from the cell. |
| insulin secretion involved in cellular response to glucose stimulus | The regulated release of proinsulin from secretory granules (B granules) in the B cells of the pancreas; accompanied by cleavage of proinsulin to form mature insulin, in response to a glucose stimulus. |
| melanosome transport | The directed movement of melanosomes into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| receptor recycling | The process that results in the return of receptor molecules to an active state and an active cellular location after they have been stimulated by a ligand. An active state is when the receptor is ready to receive a signal. |
| regulated exocytosis | A process of exocytosis in which soluble proteins and other substances are initially stored in secretory vesicles for later release. It is found mainly in cells that are specialized for secreting products such as hormones, neurotransmitters, or digestive enzymes rapidly on demand. |
| regulation of anion transport | Any process that modulates the frequency, rate or extent of the directed movement of anions, atoms or small molecules with a net negative charge into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| regulation of endocytic recycling | Any process that modulates the frequency, rate or extent of endocytic recycling. |
| regulation of protein localization to cell surface | Any process that modulates the frequency, rate or extent of protein localization to the cell surface. |
| transferrin transport | The directed movement of transferrin into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| vesicle-mediated transport | A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane. |
20 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q2TA29 | RAB11A | Ras-related protein Rab-11A | Bos taurus (Bovine) | PR |
| Q3MHP2 | RAB11B | Ras-related protein Rab-11B | Bos taurus (Bovine) | PR |
| Q5ZJN2 | RAB11A | Ras-related protein Rab-11A | Gallus gallus (Chicken) | PR |
| P62490 | RAB11A | Ras-related protein Rab-11A | Canis lupus familiaris (Dog) (Canis familiaris) | PR |
| Q8WUD1 | RAB2B | Ras-related protein Rab-2B | Homo sapiens (Human) | PR |
| P61019 | RAB2A | Ras-related protein Rab-2A | Homo sapiens (Human) | PR |
| P20338 | RAB4A | Ras-related protein Rab-4A | Homo sapiens (Human) | PR |
| P61018 | RAB4B | Ras-related protein Rab-4B | Homo sapiens (Human) | PR |
| P62491 | RAB11A | Ras-related protein Rab-11A | Homo sapiens (Human) | PR |
| P62492 | Rab11a | Ras-related protein Rab-11A | Mus musculus (Mouse) | PR |
| P46638 | Rab11b | Ras-related protein Rab-11B | Mus musculus (Mouse) | PR |
| Q52NJ1 | RAB11A | Ras-related protein Rab-11A | Sus scrofa (Pig) | PR |
| P62494 | Rab11a | Ras-related protein Rab-11A | Rattus norvegicus (Rat) | PR |
| O35509 | Rab11b | Ras-related protein Rab-11B | Rattus norvegicus (Rat) | PR |
| O04486 | RABA2A | Ras-related protein RABA2a | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9FE79 | RABA4C | Ras-related protein RABA4c | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9LH50 | RABA4D | Ras-related protein RABA4d | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9LNK1 | RABA3 | Ras-related protein RABA3 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q9LNW1 | RABA2B | Ras-related protein RABA2b | Arabidopsis thaliana (Mouse-ear cress) | PR |
| O49513 | RABA1E | Ras-related protein RABA1e | Arabidopsis thaliana (Mouse-ear cress) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MGTRDDEYDY | LFKVVLIGDS | GVGKSNLLSR | FTRNEFNLES | KSTIGVEFAT | RSIQVDGKTI |
| 70 | 80 | 90 | 100 | 110 | 120 |
| KAQIWDTAGQ | ERYRAITSAY | YRGAVGALLV | YDIAKHLTYE | NVERWLKELR | DHADSNIVIM |
| 130 | 140 | 150 | 160 | 170 | 180 |
| LVGNKSDLRH | LRAVPTDEAR | AFAEKNNLSF | IETSALDSTN | VEEAFKNILT | EIYRIVSQKQ |
| 190 | 200 | 210 | |||
| IADRAAHDES | PGNNVVDISV | PPTTDGQKPN | KLQCCQNL |